Accelerating Diagnostics in a Time of Crisis The Response to COVID-19 and a Roadmap for Future Pandemics
Book contents
- Accelerating Diagnostics in a Time of Crisis
- Accelerating Diagnostics in a Time of Crisis
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Preface
- Acknowledgments
- Introduction
- Chapter 1 Early Detection, Response, and Surveillance of the COVID-19 Pandemic Crisis
- Chapter 2 Immunology of COVID-19 and Ineffective Immunity
- Chapter 3 Clinical Management: A Roadmap Based on One New York City Hospital’s Response to the COVID-19 Pandemic
- Chapter 4 Contribution of RADx® Tech to the Rapid Development of COVID-19 Diagnostic Tests
- Chapter 5 Coordination of Resources for the Manufacturing and Deployment of COVID-19 Diagnostic Assays
- Chapter 6 Quality and Risk Management Processes for Diagnostic Assays during an Emergency Pandemic Response
- Chapter 7 Development of Assays to Diagnose COVID-19
- Chapter 8 Laboratory Verification and Clinical Validation of COVID-19 Diagnostic Assays
- Chapter 9 Importance of Timely Sequencing, Tracking, and Surveillance of Emergent Variants
- Chapter 10 The RADx® Regulatory Core and Its Role in COVID-19 Emergency Use Authorizations
- Chapter 11 Commercialization and Market Assessment of COVID-19 Assays
- Chapter 12 Testing Strategies to Mitigate COVID-19 Disease Spread
- Chapter 13 A Pandemic Not Just of Infection but of Inequality: The Social Impact of COVID-19
- Chapter 14 Summary and Path Forward for Future Pandemics
- Index
- References
Chapter 12 - Testing Strategies to Mitigate COVID-19 Disease Spread
Published online by Cambridge University Press: 06 January 2024
Book contents
- Accelerating Diagnostics in a Time of Crisis
- Accelerating Diagnostics in a Time of Crisis
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Preface
- Acknowledgments
- Introduction
- Chapter 1 Early Detection, Response, and Surveillance of the COVID-19 Pandemic Crisis
- Chapter 2 Immunology of COVID-19 and Ineffective Immunity
- Chapter 3 Clinical Management: A Roadmap Based on One New York City Hospital’s Response to the COVID-19 Pandemic
- Chapter 4 Contribution of RADx® Tech to the Rapid Development of COVID-19 Diagnostic Tests
- Chapter 5 Coordination of Resources for the Manufacturing and Deployment of COVID-19 Diagnostic Assays
- Chapter 6 Quality and Risk Management Processes for Diagnostic Assays during an Emergency Pandemic Response
- Chapter 7 Development of Assays to Diagnose COVID-19
- Chapter 8 Laboratory Verification and Clinical Validation of COVID-19 Diagnostic Assays
- Chapter 9 Importance of Timely Sequencing, Tracking, and Surveillance of Emergent Variants
- Chapter 10 The RADx® Regulatory Core and Its Role in COVID-19 Emergency Use Authorizations
- Chapter 11 Commercialization and Market Assessment of COVID-19 Assays
- Chapter 12 Testing Strategies to Mitigate COVID-19 Disease Spread
- Chapter 13 A Pandemic Not Just of Infection but of Inequality: The Social Impact of COVID-19
- Chapter 14 Summary and Path Forward for Future Pandemics
- Index
- References
Summary
The expansion of COVID-19 diagnostic testing across the USA was – and continues to be – essential to slowing and preventing the spread of COVID-19. This chapter summarizes the efforts of the Rapid Acceleration of Diagnostics (RADx®) Tech team to (1) provide science-based outputs to assess and guide specific mitigation and testing strategies, (2) demonstrate how COVID-19 prevention and containment efforts can most effectively be combined with the latest testing strategies to minimize the spread of the virus in a semi-contained population, and (3) deliver personal recommendations based on how likely an individual is to get COVID-19 and spread it to other people. Details are provided on a data-driven model to mitigate disease spread that is based on a simple counting exercise known in different disciplines as a control volume approach or queueing theory. The effects of social distancing, mask wearing, vaccination, and contact tracing on disease spread and testing requirements are explored. The US government public policy effect on testing is also discussed.
Keywords
- Type
- Chapter
- Information
- Accelerating Diagnostics in a Time of CrisisThe Response to COVID-19 and a Roadmap for Future Pandemics, pp. 236 - 249Publisher: Cambridge University PressPrint publication year: 2024
References
Kadanoff, L. P., More is the same; phase transitions and mean field theories. J Stat Phys, 137, 5–6 (2009), 777–797.CrossRefGoogle Scholar
Yim, W., Cheng, D., Patel, S. H., et al., KN95 and N95 respirators retain filtration efficiency despite a loss of dipole charge during decontamination. ACS Appl Mater Interfaces, 12, 49 (2020), 54473–54480.CrossRefGoogle ScholarPubMed
FDA, Template for developers of antigen tests (2021). www.fda.gov/media/137907/download.Google Scholar
US Department of Health and Human Services (HHS), Determination of public health emergency (2020). https://tinyurl.com/22252z7d.Google Scholar
FDA, Policy for diagnostics testing in laboratories certified to perform high complexity testing under the Clinical Laboratory Improvement Amendments prior to Emergency Use Authorization for coronavirus disease-2019 during the public health emergency; immediately in effect guidance for clinical laboratories and Food and Drug Administration staff; availability (2020). https://tinyurl.com/2s3efyse.Google Scholar
FDA, FDA issues temporary COVID-19 policy for receiving facilities and FSVP importers in meeting FSMA supplier verification onsite audit requirements (2020). https://tinyurl.com/mux3vbvr.Google Scholar
US Congress, H.R.748: Coronavirus Aid, Relief, and Economic Security Act or the CARES Act (2020). www.congress.gov/bill/116th-congress/house-bill/748.Google Scholar
US Department of Labor, Health and Human Services (HHS) and US Department of the Treasury, FAQs About Families First Coronavirus Response Act and Coronavirus Aid, Relief, And Economic Security Act Implementation Part 44 (2021). www.cms.gov/files/document/faqs-part-44.pdf.Google Scholar
Biden, J. R., Jr., National strategy for the COVID-19 response and pandemic preparedness (2021). https://tinyurl.com/ypeyuaju.Google Scholar
Occupational Safety and Health Administration (OSHA), Statement on the status of the OSHA COVID-19 vaccination and testing ETS (2022). www.osha.gov/coronavirus/ets2.Google Scholar
HHS Press Office, Biden-Harris Administration requires insurance companies and group health plans to cover the cost of at-home COVID-19 tests, increasing access to free tests (2022). https://tinyurl.com/47up6zz9.Google Scholar